Read by QxMD icon Read


Xinyu Cao, Jia Xu
Inflammation has long been proven to engage in tumor initiation and progression. Inflammasome, as a member of innate immunity-induced host defense inflammation, also plays critical roles in cancer. Inflammasome is a multiprotein complex responding to pathogen-associated molecular patterns and damage-associated molecular patterns. It is composed of receptors such as NOD-like receptors and AIM2-like receptors, adaptor protein ASC, and effector caspase-1, which can process proinflammatory cytokines interleukin (IL)-1β and IL-18...
August 13, 2019: Tumori
Antonio Mastroianni, Rossella Panella, Daniele Morelli
INTRODUCTION: The accuracy of serum neuron-specific enolase (NSE) measurements is critical, particularly in neurologic diseases and cancer. NSE measurements are compromised by slight, even invisible, hemolysis, which can produce apparently higher NSE levels, leading to inappropriate clinical decisions. In this article, we describe this issue and propose a solution for avoiding incorrect results. METHODS: Twenty blood samples from donors with NSE values that were within the reference interval were considered...
August 9, 2019: Tumori
Celeste Cagnazzo, Oriana Nanni, Francesca Arizio, Veronica Franchina, Rosita Cenna, Gianna Tabaro, Francesca Vannini, Giuseppe Procopio, Stefania Gori, Alessandro Di Costanzo
BACKGROUND: The Agenzia Italiana del Farmaco (AIFA) Determination 809/2015 sets all the requirements that clinical units and laboratories must meet in order to conduct phase I studies. Requirements include buildings, equipment, personnel, emergency management, as well as quality requirements defined in a set of standard operating procedures. METHODS: In September 2018, the Italian Association of Medical Oncology working group, Clinical Research Coordinator, created an anonymous survey addressed to 51 medical directors of oncologic/hematologic clinical phase I units and all medical directors of generic and transversal units located in Italy and listed at the AIFA website...
August 9, 2019: Tumori
Takako Wakeda, Tsuyoshi Okamura, Takuya Kawahara, Yuji Heike
BACKGROUND: Cancer treatment causes various skin appearance changes, which affect quality of life (QoL) in patients with cancer. We examined whether camouflage makeup improves QoL in these patients. METHODS: Skindex-16 and visual analogue scale scores of 39 female patients with cancer treatment-related skin changes were compared before and 2-3 months after self-administration of camouflage makeup. RESULTS: Camouflage makeup was able to conceal almost all skin changes, improving QoL scores regardless of age, diagnosis, and site of skin changes...
August 9, 2019: Tumori
Marcello Guaglio, Filiberto Belli, Alessandro Cesa Bianchi, Luca Sorrentino, Luigi Battaglia
OBJECTIVE: Rectal schwannomas are extremely rare tumors and their surgical treatment is widely variable in literature. Transanal endoscopic microsurgery (TEM) approach could be a reasonable option for such lesions, offering an organ-sparing strategy, but evidence is scarce. METHODS: We report a 69-year-old man with a rectal submucosal lesion at 10 cm from the anal verge, treated by TEM. A systematic literature review on surgical approaches in rectal schwannoma was performed...
June 25, 2019: Tumori
Marco Filetti, Raffaele Giusti, Arianna Di Napoli, Daniela Iacono, Paolo Marchetti
INTRODUCTION: The recent introduction of checkpoint inhibitor-based immunotherapy has revolutionized the treatment of advanced lung cancers, becoming standard of care in both first- and second-line treatment. New types of toxicity are emerging with the increasingly widespread use of these inhibitors. CASE PRESENTATION: We describe a case of aplastic anemia in a patient with stage IV non-small cell lung cancer after a single administration of nivolumab. CONCLUSIONS: Several similar case reports reported in literature show an increasing rate of toxicities from immunotherapy in this setting...
June 21, 2019: Tumori
Enrico Pira, Paolo Boffetta, Catalina Ciocan
No abstract text is available yet for this article.
August 2019: Tumori
(no author information available yet)
No abstract text is available yet for this article.
July 2019: Tumori
Francesco Facchinetti, Sara Pilotto, Giulio Metro, Editta Baldini, Luca Bertolaccini, Federico Cappuzzo, Angelo Delmonte, Stefano Gasparini, Alessandro Inno, Antonio Marchetti, Francesco Passiglia, Francesco Puma, Umberto Ricardi, Antonio Rossi, Lucio Crinò, Silvia Novello
The treatment landscape of metastatic non-small cell lung cancer (NSCLC) has dramatically evolved in recent years, since the recognition of several clinical-biological entities requiring personalized treatment approaches, leading to significant improvements in patients' survival outcomes. In particular, targeted therapies acting against EGFR, ALK , and ROS1 , and immunotherapeutic agents modulating the PD-1/PD-L1 axis, represent new milestones in the treatment of advanced disease, supporting a chemotherapy backbone within a multidisciplinary model...
July 2019: Tumori
Maria Giuseppa Vitale, Sergio Bracarda, Laura Cosmai, Emanuele Crocetti, Giuseppe Di Lorenzo, Alberto Lapini, Alberto Mandressi, Giuseppe Martorana, Cristina Masini, Rodolfo Montironi, Cinzia Ortega, Rodolfo Passalacqua, Camillo Porta, Giuseppe Procopio, Pierangela Sepe, Luigia Romano, Giovanni Luigi Pappagallo, Giario Conti, Michele Guida, Guido Martignoni, Franco Nolè, Sandro Pignata, Stefania Gori, Giacomo Cartenì
In the past two decades, the treatment landscape for patients with metastatic renal cell carcinoma has significantly changed thanks to the approval of several targeted molecular therapies (VEGF and mTOR inhibitors) and recently immune-checkpoint inhibitors. The Italian Association of Medical Oncology (AIOM) Renal Cell Cancer (RCC) Guidelines Panel has developed clinical guidelines to provide evidence-based information and recommendations to oncologists, urologists and all professionals involved in the management of patients with renal cell cancer...
July 2019: Tumori
Carlotta Becherini, Icro Meattini, Lorenzo Livi, Pietro Garlatti, Isacco Desideri, Vieri Scotti, Lorenzo Orzalesi, Luis Jose Sanchez, Marco Bernini, Donato Casella, Silvia Nesi, Jacopo Nori, Simonetta Bianchi, Stefania Pallotta, Livia Marrazzo
INTRODUCTION: For a long time, accelerated partial breast irradiation (APBI) effectiveness for ductal carcinoma in situ (DCIS) has been debated, due to conflicting published results. Recent encouraging data from phase 3 trials reopened new perspectives for this radiation approach. The aim of the present study was to analyze the long-term efficacy and safety results of the series of patients with DCIS enrolled in the APBI arm of the APBI-IMRT-Florence phase 3 trial (NCT02104895). METHODS: Patients were treated in a phase 3 randomized trial comparing whole breast irradiation (50 Gy in 25 fractions to the whole breast, plus 10 Gy in 5 fractions to the tumor bed) to APBI (30 Gy in 5 nonconsecutive fractions) using the intensity-modulated radiotherapy technique...
June 2019: Tumori
Carolina Espina, Linda Bauld, Bernardo Bonanni, Hermann Brenner, Karen Brown, Joakim Dillner, Ellen Kampman, Mef Nilbert, Paolo Vineis, Matty P Weijenberg, Alison Cox, Theo M de Kok, Daniela Fecht, Giota Mitrou, David C Muller, Davide Serrano, Karen Steindorf, Hans Storm, Mangesh A Thorat, Fränzel van Duijnhoven, Elisabete Weiderpass, Joachim Schüz
No abstract text is available yet for this article.
May 17, 2019: Tumori
Rosj Gallicchio, Pietro A Mastrangelo, Anna Nardelli, Pier Paolo Mainenti, Antonio P Colasurdo, Matteo Landriscina, Giuseppe Guglielmi, Giovanni Storto
Radium-223 dichloride (223 Ra) is the first, recently approved, α-particle-emitting radiopharmaceutical for the treatment of patients with bone metastases in castration-resistant prostate cancer (CRPC) and no evidence of visceral metastases. We explored MEDLINE, relevant congresses, and websites for data on 223 Ra and prostate cancer therapies, focusing on therapeutic strategies and timing, bone metastases, and diagnostic assessment. 223 Ra represents the only bone-targeting agent that has significantly extended patients' overall survival while reducing pain and symptomatic skeletal events...
May 16, 2019: Tumori
Emanuele Crocetti, Alessandra Ravaioli, Dino Amadori, Silvia Mancini, Rosa Vattiato, Orietta Giuliani, Flavia Baldacchini, Fabio Falcini
OBJECTIVES: Prognostic definition and treatment of breast cancer are supported by multigene testing. A recent trial (TAILORx) provided evidence against the use of adjuvant chemotherapy in early breast cancer (HR+ HER2-) with an intermediate result (11-25) in a multigene test (Oncotype DX). These results consequently fueled great discussion among oncologists. We aimed to estimate the burden of Italian incident breast cancer patients who, each year, may be involved in such decision-making...
May 15, 2019: Tumori
Matteo Virdis, Cristiana Bonifacio, Tatiana Brambilla, Giovanni Capretti, Pasquale De Nittis, Fara Uccelli, Alessandro Zerbi
INTRODUCTION: Though metastatic disease is a common presentation of pancreatic adenocarcinoma, localization to the penis is an extremely rare event despite its abundant vascularization. Primary cancers responsible for penile metastases usually occur in prostate and rectum and are often associated with disseminated malignancy and poor prognosis. CASE DESCRIPTION: A 66-year-old man was diagnosed with adenocarcinoma of the tail of the pancreas after the onset of thrombosis of the dorsal vein of the penis; pubis ultrasound and total body computed tomography scan were negative for metastases at other sites...
May 9, 2019: Tumori
Maria Teresa Ricci, Sara Volorio, Stefano Signoroni, Paolo Mariani, Frederique Mariette, Domenico Sardella, Valeria Pensotti, Marco Vitellaro
INTRODUCTION: Recent advances in technology and research are rapidly changing the diagnostic approach to hereditary gastrointestinal cancer (HGIC) syndromes. Although the practice of clinical genetics is currently transitioning from targeted criteria-based testing to multigene panels, important challenges remain to be addressed. The aim of this study was to develop and technically validate the performance of a multigene panel for HGIC. METHODS: CGT-colon-G14 is an amplicon-based panel designed to detect single nucleotide variants and small insertions/deletions in 14 well-established or presumed high-penetrance genes involved in HGIC...
May 8, 2019: Tumori
Milanese Gianluca, Silva Mario, Frauenfelder Thomas, Eberhard Matthias, Sabia Federica, Martini Chiara, Marchianò Alfonso, Prokop Mathias, Sverzellati Nicola, Pastorino Ugo
PURPOSE: To test ultra-low-dose computed tomography (ULDCT) scanning protocols for the detection of pulmonary nodules (PN). METHODS: A chest phantom containing 19 solid and 11 subsolid PNs was scanned on a third-generation dual-source computed tomography (CT) scanner. Five ULDCT scans (Sn100kVp and 120, 70, 50, 30, and 20 reference mAs, using tube current modulation), reconstructed with iterative reconstruction (IR) algorithm at strength levels 2, 3, 4, and 5, were compared with standard CT (120kVp, 150 reference mAs, using tube current modulation)...
May 1, 2019: Tumori
Giovanni Martino, Magda Zanelli, Andrea Marra, Martina Quintini, Maurizio Zizzo, Stefano Ascani, Maria Paola Martelli, Brunangelo Falini
BACKGROUND: Adult T-cell leukemia/lymphoma (ATLL) is an aggressive disease associated with human T-lymphotropic virus type 1 infection, with a very high prevalence in tropical areas but exceptionally rare in Europe and Western countries. CASE PRESENTATION: We describe a challenging case of ATLL in a young male patient with Brazilian origin and adopted as a child by an Italian family, presenting to our clinic with atypical T-lymphocytosis and life-threatening lung infections...
May 1, 2019: Tumori
Andrea Ferrari, Laura Veneroni, Anna Romani, Elena Pagani Bagliacca, Paola Gaggiotti, Matteo Silva, Stefano Signoroni, Maura Massimino
This article describes a brief account written by a girl treated with chemotherapy and surgery for an ovarian germ cell tumor. The brief novel was conceived in the context of the Youth Project of Milan, dedicated to helping adolescent and young adult cancer patients socialize and express themselves through group activities that focus on art and creativity. It describes the scenery of a new galaxy and is replete with images and metaphors that recall the experience of receiving anticancer treatment, touching on emotional themes including desire, isolation, fear, and hope...
April 26, 2019: Tumori
Eufra Van Damme, Maja Kiselinova, Elke Van Schoote
INTRODUCTION: Anaplastic lymphoma kinase ( ALK) gene translocation occurs in 3%-5% of patients with non-small cell lung cancer (NSCLC), typically in younger patients. Crizotinib (tyrosine kinase inhibitor) has been considered as the standard of care for advanced ALK-positive lung cancer but it only gives a median progression-free survival of 7.7-11 months. CASE: A 41-year-old old man, former smoker, was diagnosed with NSCLC in the right lung with manifest pleural effusion...
April 26, 2019: Tumori
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"